Sanofi Aventis De Panama S.A. | Supplier Report — Panjiva
MENU

Supply Chain Intelligence about:

Sanofi Aventis De Panama S.A.

Company profile   France

See Sanofi Aventis De Panama S.A.'s products and customers

Thousands of companies like you use Panjiva to research suppliers and competitors.

Easy access to trade data

Cleaned and organized South American shipments

4 South American shipments available for Sanofi Aventis De Panama S.A.
Date Data Source Customer Details
2016-07-26 Paraguay Imports
SANOFI AVENTIS PARAGUAY S.A
CLEXANE, CLEXANE 40MG/0.4ML INJ PS2 ERIS XB(ENOXAPARINA SODICA)
2019-06-03 Paraguay Imports
SANOFI AVENTIS S.A
SANOFI, LOS DEMAS MEDICAMENTOS PARA USO HUMANO EN,: CLEXANE 80 MG/O 8ML INJ PS2 ERIS XB
2019-06-03 Paraguay Imports
SANOFI AVENTIS S.A
SANOFI, LOS DEMAS MEDICAMENTOS PARA USOHUMANO EN,: CLEXANE 60MG/0.6ML INJ PS2 ERIS XB
Shipment data shows what products a company is trading and more. Learn more

Explore trading relationships hidden in supply chain data


Sample Bill of Lading

4 shipment records available

Bill of Lading Number
XXX 00998578
Shipment Date
2016-07-26
Consignee
Sanofi Aventis Paraguay S.A
Consignee (Original Format)
SANOFI AVENTIS PARAGUAY S.A
Consignee Tax Number
800355741
Shipper
Sanofi Aventis De Panama S.A.
Shipper (Original Format)
SANOFI AVENTIS PARAGUAY SA
Carrier
TAMPA CARGO S.A.
Carrier Country (Original Format)
COLOMBIA
Shipment Origin
France
Shipment Origin (Original Format)
FRANCIA
Port of Unlading
Paraguay (PY)
Country of Sale
Panama
Country of Sale (Original Format)
PANAMA
Transport Method
Air
HS Code
30049099
Goods Shipped
CLEXANE 40MG/0.4ML INJ PS2 ERIS XB(ENOXAPARINA SODICA)
Item Quantity
23000
Item Unit
unid.
Gross Weight (kg)
1517
Net Weight (kg)
191
Value of Goods, CIF (USD)
$190,662
Value of Goods, FOB (USD)
$182,027
Freight Value (USD)
$7,974
Value of Goods, Item FOB (USD)
$8
Insurance Value (USD)
$661
Manifest Number
16002MANI010727T
Brand
CLEXANE

Recent Panjiva Research about Sanofi Aventis De Panama S.A.

20161202-insulin-us

Novo and Lilly Face Tough Growth in Diabetes, Trade Data Shows

The global prevalence of diabetes is growing, but can be a tough sector for pharmaceutical companies to make money in as recent results from Novo Nordisk and Eli Lilly demonstrate. Panjiva data shows that U.S. imports of insulin and related equipment fell 15% in the third quarter in dollar ter... Read more →